Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06320626` - Pharmacokinetic-guided Dosing of Emicizumab	Phase 4
Completed	`NCT04072237` - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia	Phase 1
Not yet recruiting	`NCT02554526` - Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors	N/A
Completed	`NCT03818529` - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Active, not recruiting	`NCT03619863` - ATHN 7: Hemophilia Natural History Study
Recruiting	`NCT06010953` - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment	Phase 1/Phase 2
Completed	`NCT03951103` - rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
Recruiting	`NCT05888870` - ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor	Phase 4
Terminated	`NCT04303572` - The Hemophilia Inhibitor Eradication Trial	Phase 3
Terminated	`NCT04489537` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B	Phase 3
Terminated	`NCT04548791` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders	Phase 1/Phase 2
Completed	`NCT06357572` - Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
Recruiting	`NCT04647227` - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors	Phase 4
Completed	`NCT03372993` - Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Terminated	`NCT03204539` - INdividualized ITI Based on Fviii(ATE) Protection by VWF	Phase 4
Active, not recruiting	`NCT04205175` - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab	Phase 4
Recruiting	`NCT06312475` - Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors	Phase 3
Recruiting	`NCT03598725` - Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China	Phase 4
Completed	`NCT04723693` - An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Completed	`NCT04789954` - Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors	Early Phase 1

NCT number	NCT04768699
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Lei Zhang, Doctor
Phone	13502118379
Email	zhanglei1@ihcams.ac.cn
Status	Recruiting
Phase	Phase 1
Start date	December 1, 2020
Completion date	December 1, 2021

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms